Log in

NYSE:ELANElanco Animal Health Stock Price, Forecast & News

$24.30
-0.14 (-0.57 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$24.17
Now: $24.30
$24.58
50-Day Range
$21.00
MA: $22.48
$25.28
52-Week Range
$15.17
Now: $24.30
$32.66
Volume2.88 million shs
Average Volume5.74 million shs
Market Capitalization$9.69 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.91
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production. It sells its products to third-party distributors; veterinarians; and food animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated has a research and development collaboration with AgBiome, Inc. to develop nutritional health products for swine. The company was founded in 1954 and is headquartered in Greenfield, Indiana.
Read More
Elanco Animal Health logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.07 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone877-352-6261

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.07 billion
Cash Flow$1.90 per share
Book Value$16.68 per share

Profitability

Net Income$67.90 million

Miscellaneous

Employees6,080
Market Cap$9.69 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$24.30
-0.14 (-0.57 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ELAN News and Ratings via Email

Sign-up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Elanco Animal Health (NYSE:ELAN) Frequently Asked Questions

How has Elanco Animal Health's stock been impacted by COVID-19 (Coronavirus)?

Elanco Animal Health's stock was trading at $23.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ELAN stock has increased by 2.4% and is now trading at $24.30.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Elanco Animal Health?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Elanco Animal Health
.

When is Elanco Animal Health's next earnings date?

Elanco Animal Health is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Elanco Animal Health
.

How were Elanco Animal Health's earnings last quarter?

Elanco Animal Health (NYSE:ELAN) released its quarterly earnings data on Thursday, July, 30th. The company reported $0.09 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.02 by $0.07. The firm had revenue of $586.30 million for the quarter, compared to the consensus estimate of $555.84 million. Elanco Animal Health had a negative net margin of 3.63% and a positive return on equity of 4.68%.
View Elanco Animal Health's earnings history
.

What guidance has Elanco Animal Health issued on next quarter's earnings?

Elanco Animal Health issued an update on its third quarter 2020 Pre-Market earnings guidance on Thursday, July, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $660-710 million, compared to the consensus revenue estimate of $785.5 million.

What price target have analysts set for ELAN?

10 brokerages have issued 12 month target prices for Elanco Animal Health's shares. Their forecasts range from $19.00 to $32.00. On average, they expect Elanco Animal Health's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price.
View analysts' price targets for Elanco Animal Health
.

Has Elanco Animal Health been receiving favorable news coverage?

Headlines about ELAN stock have trended extremely negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Elanco Animal Health earned a news sentiment score of -4.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Elanco Animal Health
.

Who are some of Elanco Animal Health's key competitors?

What other stocks do shareholders of Elanco Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), Micron Technology (MU), AbbVie (ABBV), Walt Disney (DIS), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Home Depot (HD) and Pfizer (PFE).

Who are Elanco Animal Health's key executives?

Elanco Animal Health's management team includes the following people:
  • Mr. Jeffrey N. Simmons, Pres, CEO & Director (Age 52)
  • Mr. Todd S. Young, Exec. VP & CFO (Age 47)
  • Mr. David S. Kinard, Exec. VP of HR (Age 52)
  • Ms. Sarena S. Lin, Exec. VP of Elanco USA, Corp. Strategy & Global Marketing (Age 48)
  • Mr. David Alan Urbanek, Exec. VP of Manufacturing & Quality (Age 53)

When did Elanco Animal Health IPO?

(ELAN) raised $1.4 billion in an IPO on Thursday, September 20th 2018. The company issued 62,900,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

What is Elanco Animal Health's stock symbol?

Elanco Animal Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELAN."

Who are Elanco Animal Health's major shareholders?

Elanco Animal Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include UBS Group AG (2.77%), Vantage Investment Partners LLC (0.79%), Sumitomo Mitsui Trust Holdings Inc. (0.42%), Swiss National Bank (0.40%), Academy Capital Management Inc. TX (0.27%) and Douglas Lane & Associates LLC (0.23%). Company insiders that own Elanco Animal Health stock include Art A Garcia, David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral and Todd S Young.
View institutional ownership trends for Elanco Animal Health
.

Which institutional investors are selling Elanco Animal Health stock?

ELAN stock was sold by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Wafra Inc., DekaBank Deutsche Girozentrale, Three Peaks Capital Management LLC, Arizona State Retirement System, New York State Common Retirement Fund, Raymond James & Associates, and WINTON GROUP Ltd.
View insider buying and selling activity for Elanco Animal Health
.

Which institutional investors are buying Elanco Animal Health stock?

ELAN stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Academy Capital Management Inc. TX, Public Employees Retirement Association of Colorado, Douglas Lane & Associates LLC, Janney Capital Management LLC, Envestnet Asset Management Inc., Sanders Morris Harris LLC, and Sciencast Management LP. Company insiders that have bought Elanco Animal Health stock in the last two years include Art A Garcia, David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral, and Todd S Young.
View insider buying and selling activity for Elanco Animal Health
.

How do I buy shares of Elanco Animal Health?

Shares of ELAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Elanco Animal Health's stock price today?

One share of ELAN stock can currently be purchased for approximately $24.30.

How big of a company is Elanco Animal Health?

Elanco Animal Health has a market capitalization of $9.69 billion and generates $3.07 billion in revenue each year. The company earns $67.90 million in net income (profit) each year or $1.06 on an earnings per share basis. Elanco Animal Health employs 6,080 workers across the globe.

What is Elanco Animal Health's official website?

The official website for Elanco Animal Health is www.elanco.com.

How can I contact Elanco Animal Health?

Elanco Animal Health's mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company can be reached via phone at 877-352-6261.

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.